70岁及以上激素受体阳性早期乳腺癌保乳术后单纯激素治疗或单纯放疗:美国国家癌症数据库分析
该研究基于美国国家癌症数据库(2010-2014),纳入2995例70岁及以上、Charlson/Deyo评分0-1、T1N0激素受体阳性HER-2阴性早期乳腺癌保乳术后接受单纯激素治疗或单纯放疗的患者,采用倾向性评分匹配分析。中位随访45个月,单纯激素治疗与单纯放疗的总生存率无差异(85%对86%,P=.44),多因素分析中治疗方式与总生存无关(HR 1.13,95%CI 0.85-1.49,P=.406)。
要点
- 健康老年早期乳腺癌保乳术后,单纯激素治疗与单纯放疗总生存无差异。
- 多因素分析中年龄、CD评分1和居住于大都市区与较差总生存相关。
- 中位随访45个月,激素治疗组与放疗组总生存率分别为85%和86%。
核心结论
- 对于接受保乳术的健康老年生物学有利乳腺癌患者,辅助放疗或辅助激素治疗与等效的5年总生存率相关。
- 需要随机对照试验来探索老年激素受体阳性乳腺癌患者的辅助单一治疗选择。
研究设计与样本
- 回顾性队列研究,检索美国国家癌症数据库2010-2014年数据。
- 纳入2995例70岁及以上、Charlson/Deyo评分0-1、T1N0激素受体阳性HER-2阴性早期乳腺癌保乳术后接受辅助激素治疗或放疗的患者,中位年龄78岁。
- 采用倾向性评分匹配患者进行分析。
主要发现
- 81%患者Charlson/Deyo评分为0,77%为临床IA期;65%接受单纯激素治疗,35%接受单纯放疗。
- 匹配队列多因素分析中,年龄较大(HR 1.10;95%CI 1.07-1.13;P<.001)、CD评分1(HR 1.92;95%CI 1.37-2.70;P=.0002)和居住于大都市区(HR 3.09;95%CI 1.43-6.67;P=.004)与较差总生存相关。
- 激素治疗对比放疗与总生存无关(HR 1.13;95%CI 0.85-1.49;P=.406)。
- 中位随访45个月,激素治疗组与放疗组总生存率分别为85%和86%(P=.44)。
临床怎么用
- 对于健康老年生物学有利早期乳腺癌保乳术后患者,可考虑单纯激素治疗或单纯放疗作为辅助治疗选择。
- 临床决策时需结合年龄、合并症评分和居住地区等因素综合评估。
局限性
- 为回顾性数据库分析,非随机对照试验,存在选择偏倚可能。
- 中位随访仅45个月,长期生存差异未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Deintensification of adjuvant therapy is being considered for older women with early-stage, biologically favorable breast cancer. Although radiation therapy (RT) can be omitted in some cases, toxicity from hormone therapy (HT) is not trivial, and adherence rates vary. We hypothesized that adjuvant RT alone would produce survival outcomes comparable to those with adjuvant HT alone among elderly patients treated with lumpectomy. METHODS AND MATERIALS: We searched the National Cancer Database (2010-2014) for healthy women (aged ≥70 years, Charlson/Deyo [CD] score 0-1) with T1N0 hormone-receptor-positive, HER-2-negative breast cancer treated with lumpectomy and adjuvant HT or RT. Propensity scores were used to match patients for analysis. RESULTS: We identified 2995 patients (median age, 78 years), most (81%) with a CD score of 0, clinical stage IA (77%), of whom 65% received HT alone and 35% received RT only after lumpectomy. On multivariate analysis of the matched cohort, older age (hazard ratio [HR] 1.10; 95% confidence interval [CI] 1.07-1.13; P < .001), CD score 1 (HR 1.92; 95% CI 1.37-2.70; P = .0002), and living in a metropolitan (vs urban) area (HR 3.09; 95% CI 1.43-6.67; P = .004) were associated with inferior overall survival (OS), whereas treatment with HT (vs RT) was not (HR 1.13; 95% CI 0.85-1.49; P = .406). At a median follow-up of 45 months, no difference was found in OS between HT versus RT cohorts (85% and 86%, respectively; P = .44). CONCLUSIONS: For healthy, older women with biologically favorable breast cancer treated with lumpectomy, adjuvant RT or HT is associated with equivalent 5-year OS rates. A randomized controlled trial is warranted to explore these adjuvant monotherapy options in elderly patients with hormone receptor-positive breast cancer.
引用
- Buszek SM, Lin HY, Bedrosian I, et al. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys. 2019. PMID: 31377160. doi:10.1016/j.ijrobp.2019.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。